Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BOOST cells are allogeneic, fetal liver-derived mesenchymal stem cells (MSCs) expanded from first-trimester fetal tissue. They are being developed for the treatment of severe osteogenesis imperfecta (OI), a genetic disorder characterized by fragile bones due to defects in type I collagen. The therapy is designed to provide healthy MSCs that can engraft in the patient's bone and differentiate into osteoblasts, which then produce functional type I collagen. The BOOST2B clinical trial, a collaboration between Christian Medical College, Vellore, and BOOST Pharma, is evaluating the safety and efficacy of these cells when administered through both intravenous and intraosseous routes in children with severe OI.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BOOST cells.